LCM
AERI

Legato Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Legato Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-38,846
Closed -$2.32M – 232
2017
Q4 		$2.32M Sell
38,846
-2,000
-5% -$121K 0.33% 89
2017
Q3 		$1.99M Buy
40,846
+341
+0.8% +$18.6K 0.3% 98
2017
Q2 		$2.13M Buy
+40,505
New +$1.89M 0.91% 19

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Legato Capital Management's AERI Position: Q1 2018 in Review

Legato Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q1 2018, closing a stake of 38,846 shares — an estimated $2.32M sold.

Legato Capital Management first reported a position in AERI in Q2 2017 and held it in 3 quarters. The position peaked at $2.32M in Q4 2017. 172 funds tracked by Wall St. Rank hold AERI as of Q1 2018.

  • Legato Capital Management reported no remaining Aerie Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Legato Capital Management sold 38,846 Aerie Pharmaceuticals shares in Q1 2018, an estimated $2.32M.
  • Legato Capital Management first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Legato Capital Management's Aerie Pharmaceuticals position peaked at $2.32M in Q4 2017.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2018.

Based on Legato Capital Management's 13F filing for Q1 2018, filed 19 Apr 2018.